Clinical trials: Poor Performance Status
Malignant Tumor of Lung, Poor Performance Status
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the…
- Trial name
- NCT05826483
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Small Cell Lung Cancer
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
This is a multicenter, single-arm, exploratory clinical study designed to observe and evaluate the efficacy and safety of adebrelimab combined with oral etoposide for elderly patients and patients with poor performance status in…
- Trial name
- NCT07398560
- Testing
- Adebrelimab, Oral etoposide soft capsules
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The Third Affiliated Hospital of Harbin Medical University
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00389584
- Testing
- irinotecan hydrochloride, cognitive assessment, management of therapy complications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Poor Performance Status, Cognition - Other
Innovative Training Program for Elderly in Need of Care
The goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration [SR-WBV] and virtual virtual games [VG]) in the skilling up phase on…
- Trial name
- NCT02332083
- Testing
- SR-WBV, Exergame, Aktiv Tramp
- Where
- Switzerland
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bern University of Applied Sciences
Small-cell Lung Cancer
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
The SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2).
- Trial name
- SPACE-T (NCT07803848)
- Testing
- Tarlatamab
- Where
- 8 sites in Germany
- Volunteers
- 57 people
- Sponsor
- AIO-Studien-gGmbH
Lung Cancer
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
The goal of this clinical research study is to learn how effective the drug pemetrexed (ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS) (inability to perform every day activities without…
- Trial name
- NCT00508144
- Testing
- Alimta
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Because of the demonstrated single agent activity and excellent tolerability in patients with refractory non-small cell lung cancer, ZD1839 may be of benefit in the first-line treatment of patients with advanced non-small cell…
- Trial name
- NCT00193336
- Testing
- ZD1839
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Deep Vein Thrombosis, Cancer
US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status
The aim of this study is to determine the prevalence of asymptomatic lower extremity DVT detected by US-Doppler and procoagulant microparticles in a selected group of cancer patients suffering from an advanced stage of the…
- Trial name
- NCT00336258
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Poor Performance Status
Minocycline Treatment in Acute Hemorrhagic Stroke
The investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on…
- Trial name
- Minocycline (NCT01388127)
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Wolfson Medical Center
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status
The goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and…
- Trial name
- HNSCC (NCT07796126)
- Testing
- Toripalimab, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-Small Cell Lung Cancer
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern…
- Trial name
- NCT00085839
- Testing
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- OSI Pharmaceuticals
Cognitive Impairment, Poor Nutrition
The PROtein Enriched MEDiterranean Diet and EXercise Trial for Older Adults At Risk of Undernutrition
PROMED-EX is a single-blind, parallel group randomised controlled trial to determine the effect of a PROtein enriched MEDiterranean diet (PROMED) in comparison to a PROtein enriched MEDiterranean diet and EXercise (PROMED-EX)…
- Conditions
- Cognitive Impairment, Poor Nutrition, Cognitive Decline
- Trial name
- PROMED-EX (NCT05166564)
- Testing
- A Protein Enriched Mediterranean Diet (PROMED) Intervention, A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention
- Where
- United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Metastatic Cancer
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00006259
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
NSCLC Stage IV, KRAS P.G12C
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The…
- Trial name
- ADEPPT (NCT05673187)
- Testing
- Adagrasib
- Where
- 18 sites in Belgium, France and 4 more
- Volunteers
- 68 people
- Sponsor
- ETOP IBCSG Partners Foundation
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00287859
- Testing
- topotecan hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01839981
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00124618
- Testing
- cetuximab, radiation therapy
- Where
- 175 sites in United States
- Volunteers
- 58 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer (NSCLC)
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to…
- Trial name
- NCT05589818
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC